BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9177428)

  • 1. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.
    Cortes J; Kantarjian H; Talpaz M; O'Brien S; Beran M; Koller C; Keating M
    Leukemia; 1997 Jun; 11(6):788-91. PubMed ID: 9177428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purine nucleoside analogues in the treatment of myleoid leukemias.
    Robak T
    Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
    Cheson BD; Vena DA; Barrett J; Freidlin B
    J Clin Oncol; 1999 Aug; 17(8):2454-60. PubMed ID: 10561309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Kantarjian H; O'Brien S; Beran M; Estey E; Keating M; Talpaz M
    Leukemia; 1997 Jul; 11(7):929-32. PubMed ID: 9204970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
    Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
    J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up.
    Seymour JF; Talpaz M; Kurzrock R
    Leukemia; 1997 Jan; 11(1):42-7. PubMed ID: 9001417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
    Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
    Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia.
    Rodriguez-Monge EJ; Cortes JE; O'Brien S; Talpaz M; Kantarjian HM
    Cancer; 1997 Aug; 80(3):396-400. PubMed ID: 9241073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
    Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase.
    Russo D; Regazzi M; Sacchi S; Visani G; Lazzarino M; Avvisati G; Pelicci PG; Dastoli G; Grandi C; Iacona I; Candoni A; Grattoni R; Galieni P; Rupoli S; Liberati AM; Maiolo AT
    Leukemia; 1998 Apr; 12(4):449-54. PubMed ID: 9557600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
    Kantarjian HM; Talpaz M; Hester J; Feldman E; Korbling M; Liang J; Rios MB; Smith TL; Calvert L; Deisseroth AB
    J Clin Oncol; 1995 Mar; 13(3):553-9. PubMed ID: 7884415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
    Weiss MA; Maslak PG; Jurcic JG; Scheinberg DA; Aliff TB; Lamanna N; Frankel SR; Kossman SE; Horgan D
    J Clin Oncol; 2003 Apr; 21(7):1278-84. PubMed ID: 12663715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
    Korycka A; Robak T
    Arch Immunol Ther Exp (Warsz); 2003; 51(1):61-7. PubMed ID: 12691305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results.
    Cortes JE; Talpaz M; Beran M; O'Brien SM; Rios MB; Stass S; Kantarjian HM
    Cancer; 1995 Jan; 75(2):464-70. PubMed ID: 7812917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.